ROLE OF PLATELET-ACTIVATING-FACTOR IN GENTAMICIN AND CISPLATIN NEPHROTOXICITY

被引:38
|
作者
DOSSANTOS, OFP [1 ]
BOIM, MA [1 ]
BARROS, EJG [1 ]
SCHOR, N [1 ]
机构
[1] ESCOLA PAULISTA MED SCH,DEPT MED,DIV NEPHROL,RUA BOTUCATU 740,BR-04023 SAO PAULO,BRAZIL
基金
巴西圣保罗研究基金会;
关键词
D O I
10.1038/ki.1991.269
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The present study was undertaken to evaluate the effects of platelet activating factor (PAF) antagonists on nephrotoxicity induced by gentamicin (GENTA) and cisplatin (DDP) in rats. PAF infusion provoked a 56% decline in single nephron (SN) GFR due to a decrease in glomerular plasma flow (Q(A), 55%), glomerular transcapillary hydraulic pressure (DELTA-P, 13%), and glomerular ultrafiltration coefficient (K(f), 37%). Four days after a single dose of DDP (6 mg/kg, i.p.) we observed non-oliguric acute renal failure (ARF) with reduced SNGFR (45%), Q(A) (46%) and DELTA-P (10%) and unchanged K(f). GENTA administration for 10 days (40 mg/kg, i.p. daily) induced a decline in SNGFR (40%), Q(A) (41%) and K(f) (41%). Chronic treatment with a GENTA + PAF antagonist (BN 52021) partially prevented the decline in SNGFR (22%) by an amelioration in Q(A) (25%) and K(f) (13%). However, simultaneous treatment with DDP and BN 52063 completely prevented the ARF induced by DDP, normalizing all parameters of renal function. Thus, PAF may be a potential mediator involved in the nephrotoxicity induced by GENTA and DDP.
引用
收藏
页码:742 / 747
页数:6
相关论文
共 50 条
  • [21] PHARMACOLOGY OF PLATELET-ACTIVATING-FACTOR
    BRAQUET, P
    VARGAFTIG, BB
    TRANSPLANTATION PROCEEDINGS, 1986, 18 (05) : 10 - 19
  • [22] PLATELET-ACTIVATING-FACTOR AND THE CIRCULATION
    VANDONGEN, R
    JOURNAL OF HYPERTENSION, 1991, 9 (09) : 771 - 778
  • [23] PLATELET-ACTIVATING-FACTOR ANTAGONISTS
    KOLTAI, M
    BRAQUET, PG
    CLINICAL REVIEWS IN ALLERGY, 1994, 12 (04): : 361 - 380
  • [24] PLATELET-ACTIVATING-FACTOR AND ASTHMA
    MORLEY, J
    AGENTS AND ACTIONS, 1986, 19 (1-2): : 100 - 108
  • [25] ANTAGONISTS OF PLATELET-ACTIVATING-FACTOR
    TOKUMURA, A
    TSUKATANI, H
    SEIKAGAKU, 1985, 57 (12): : 1618 - 1623
  • [26] PLATELET-ACTIVATING-FACTOR ANTAGONISTS
    SAUNDERS, RN
    HANDLEY, DA
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1987, 27 : 237 - 255
  • [27] PLATELET-ACTIVATING-FACTOR AND ISCHEMIA
    POTRON, G
    PETITFRERE, E
    NGUYEN, P
    CLINICAL HEMORHEOLOGY, 1993, 13 (02): : 155 - 176
  • [28] PLATELET-ACTIVATING-FACTOR RECEPTOR
    IZUMI, T
    TAKANO, T
    BITO, H
    NAKAMURA, M
    MUTOH, H
    HONDA, Z
    SHINIZU, T
    JOURNAL OF LIPID MEDIATORS AND CELL SIGNALLING, 1995, 12 (2-3): : 429 - 442
  • [29] THE PROMISE OF PLATELET-ACTIVATING-FACTOR
    BRAQUET, P
    MENCIAHUERTA, JM
    CHABRIER, PE
    TOUQUI, L
    VARGAFTIG, BB
    ISI ATLAS OF SCIENCE-PHARMACOLOGY, 1987, 1 (03): : 187 - 198
  • [30] RADIOIMMUNOASSAY FOR PLATELET-ACTIVATING-FACTOR
    KARASAWA, K
    SATOH, N
    HONGO, T
    NAKAGAWA, Y
    SETAKA, M
    NOJIMA, S
    LIPIDS, 1991, 26 (12) : 1126 - 1129